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After our recent discovery of a Streptococcus pneu-
moniae 19A “superbug” (Legacy strain) that is resistant 
to all Food and Drug Administration–approved antimicro-
bial drugs for treatment of acute otitis media (AOM) in chil-
dren, other S. pneumoniae isolates from children with AOM 
were characterized by multilocus sequence typing (MLST). 
Among 40 isolates studied, 16 (40%) were serotype 19A, 
and 9 (23%) were resistant to multiple antimicrobial drugs. 
Two others had unreported sequence types (STs) that ex-
pressed the 19A capsule, and 8 (88%) of the 9 multidrug-
resistant strains were serotype 19A, including the Legacy 
strain with the new ST-2722. In genetic relatedness, ST-
2722 belonged to a cluster of reported strains of S. pneumo-
niae in which all strains had 6 of the same alleles as ST-156. 
The multidrug-resistant strains related to ST-156 expressed 
different capsular serotypes: 9V, 14, 11A, 15C, and 19F.
The increasing global emergence and rapid spread of 
multidrug-resistant Streptococcus pneumoniae is a serious 
concern (1,2). Clonal dissemination of problematic pneu-
mococcal strains have created clinically important treatment 
problems (3,4). Pneumococcal resistance to antimicrobial 
drugs was ﬁ  rst reported in the mid-1960s (5,6). Since 1990, 
drug-resistant isolates of S. pneumoniae have spread rap-
idly throughout the United States (7). In the early 1990s, 
high-level resistance to penicillin and other antimicrobial 
drugs appeared in the United States with a low prevalence 
(8). Over the past decade, multidrug-resistant clones of S. 
pneumoniae have rapidly emerged (8–11). Of 90 serotypes, 
19A is one of the most common types found in children. It 
can cause severe disease and easily develop antimicrobial 
drug resistance (9). The ﬁ  rst 19A strain of S. pneumoniae 
with penicillin resistance was reported in the United States 
in 1986 (12). Introduction in 2000 of a pneumococcal 7-va-
lent pneumococcal conjugate vaccine (PCV7) in the United 
States has substantially curtailed pneumococcal infections 
caused by 7 vaccine strains in children (13–15). However, 
nonvaccine strains, including drug-resistant strains, are in-
creasingly being identiﬁ  ed in patients. Among multidrug-
resistant strains, a high proportion is serotype 19A, a strain 
not included in the vaccine; however, the proportion of in-
vasive pneumococcal diseases caused by serotype 19A has 
substantially increased (8–11).
We recently discovered and reported a “superbug” 
strain of S. pneumoniae (Legacy strain) that is resistant to 
all Food and Drug Administration (FDA)–approved anti-
microbial drugs and to 8 non-FDA–approved antimicrobial 
drugs used to treat acute otitis media (AOM) in children 
(11). Using molecular epidemiologic methods, particularly 
multilocus sequence typing (MLST), we characterized the 
molecular type of multidrug-resistant strains of S. pneumo-
niae recently isolated from children with AOM, compared 
the Legacy strain sequence type (ST) 2722 with 67 strains 
with the closest types in the MLST database, and reported 
the likely evolution and spread of the ancestor strains of the 
Legacy strain.
Methods
Pneumococcal Isolates, Serotype Analysis, 
and Antimicrobial Drug–Susceptibility Testing
All pneumococcal bacteria were isolated from children 
seen at a private pediatric group in suburban Rochester, 
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New York (Legacy Pediatrics). Isolates were obtained from 
middle ear ﬂ  uid of children with AOM at 6–36 months of 
age during 2004–2006. The children received age-appro-
priate inoculations with PCV7 at 2, 4, 6, and 12–15 months 
of age. The University of Rochester Institutional Review 
Board approved the study, and written informed consent 
was obtained from parents or guardians for the study and 
for all tympanocentesis procedures. Serotypes of pneumo-
cocci were determined by latex agglutination (Pneumotest-
Latex; Statens Serum Institute, Copenhagen, Denmark) ac-
cording to the manufacturer’s instructions and conﬁ  rmed 
by Quelling reaction. The antimicrobial drug susceptibility 
of pneumococci was determined as described previously by 
Etest or microbroth dilution (11).
Multilocus Sequence Typing
The internal fragments of 7 housekeeping genes (aroE 
[shikimate dehydrogenase], gdh [glucose-6-phosphate de-
hydrogenase], gki [glucose kinase], recP [transketolase], 
spi [signal peptidase I], xpt [xanthine phosphoribosyltrans-
ferase], and ddl [D-alanine-D-alanine ligase]) were ampli-
ﬁ  ed from chromosomal DNA by PCR. Chromosomal DNA 
was extracted from subculture of S. pneumoniae isolations 
recovered from middle ear ﬂ  uid, nasal wash, or nasal swabs. 
PCR ampliﬁ  cation was performed using primer pairs aroE-
up, 5′-GCCTTTGAGGCGACAGC-3′ and aroE-dn, 5′-TGC
AGTTCA(G/A)AAACAT(A/T)TTCTAA-3′;  gdh-up, 5′-
ATGGACAAACCAGC (G/A/T/C)AG(C/T)TT-3′ and gdh-
dn, 5′-GCTTGAGGTCCCAT(G/A)CT(G/A/T/C) CC-3′; 
gki-up, 5′-GGCATTGGAATGGGATCACC-3′ and gki-dn, 
5′-TCTCCCGCAGCTGACAC-3′; recP-up, 5′-GCCAACT
CAGGTCATCCAGG-3′ and recP-dn, 5′-TGCAACCG
TAGCATTGTAAC-3′; and spi-up, 5′-TTATTCCTCCT
GATTCTGTC-3′ and spi-dn, 5′-GTGATTGGCCAGA
AGCGGAA-3′. PCR conditions were as follows: initial 
denaturation at 95°C for 5 min, followed by 30 cycles of 
95°C for 30 s; annealing at 50°C–55°C for 30 s; and ex-
tension at 72°C for 30 s. The ampliﬁ  ed DNA fragments 
were puriﬁ   ed by using QIAquick PCR Puriﬁ  cation  Kit 
(QIAGEN, Valencia, CA, USA) and were sequenced in 
each direction by using the same primers used for ampli-
ﬁ  cation and by using the BigDye Terminator v3.1 Cycle 
Sequencing Kit on an Applied Biosystems Prism 377 
automated sequencer (Applied Biosystems, Foster City, 
CA, USA).
The sequences at each of the 7 loci were then com-
pared with the sequences of all of the known alleles at those 
loci in the database at the pneumococcal MLST website 
(http://spneumoniae.mlst.net). The sequences identical to 
a known sequence were assigned the same allele number, 
and nonidentities to any known allele sequences were as-
signed new allele numbers. The allele at each of the 7 loci 
deﬁ  nes the allelic proﬁ  le of each strain, as well as its ST. 
New allelic number or new ST number was assigned by a 
curator of the pneumococcal MLST database. The related-
ness of isolates and known similar strains in the database 
was determined by constructing a neighbor-joining tree us-
ing a program online, Draw Tree Using Own MLST Data, 
found at the pneumococcal MLST website.
Results
Among 40 S. pneumoniae isolates recovered from 
middle ear ﬂ  uid of children with AOM, 16 (40%) were se-
rotype 19A. Serotype 19A was the most common serotype 
isolated in the study during 2004–2006.
Antimicrobial drug susceptibility testing was per-
formed on the serotype 19A isolates. Eight (50%) of the 16 
isolates of 19A were highly penicillin resistant (MIC >2.0 
μg/mL), and all 8 were also multidrug resistant.
MLST of these16 S. pneumoniae isolates with sero-
type 19A showed that 6 (38%) were ST-320; 3 (19%) were 
ST-199; 2 (13%) were unreported STs now assigned ST- 
2722 and ST-2704; 2 (13%) were ST-1673; and 1 (6%) 
each of the remaining 3 was ST-1451, ST-2265, and ST-
63. Among the 8 multidrug-resistant isolates, 5 (63%) were 
ST-320, 1 (13%) was ST-1451, and 1 (13%) was the newly 
assigned ST-2722 (Table 1, Figure 1). The genetic distance 
of the Legacy strain is closest to 7 other multidrug-resistant 
strains with ST-320 and ST-1451 in our group of 40 recent 
isolates.
To determine the evolutionary relationship of the 
Legacy strain (ST-2722) to other strains, we constructed a 
neighbor-joining tree. ST-2722 is assumed to have genetic 
relatedness to another ST in the database when an ST has 
>5 of the same loci as ST-2722 (Figure 2). ST-2722 be-
longed to a cluster in which all strains have 6 of 7 same loci. 
This cluster consisted of 59 (88%) strains with molecular 
type ST-156 and 1 strain each with ST-2722, ST-2128, ST-
1227, ST-2616, ST-1893, ST-334, ST-1556, ST-2684, and 
ST-1697. The major dissimilarity of strains in this cluster 
was on loci recP (Table 2, Figure 3). The recP gene had 3 
major variable sites at the 10th, 121st, and 368th bp among 
strains. For instance, the DNA at the 10th, 121st, and 368th 
bp are T, C, T, respectively, in ST-2722; C, T, T in ST-156; 
and C, T, C in ST-2128 (Figure 3).
Forty-three (64%) of the 67 strains related to ST-2722 
were penicillin resistant, and 28 (42%) of these strains were 
resistant to at least 1 other antimicrobial drug. Thirty-four 
(51%) of the 67 strains related to ST-2722 serotype 19A 
strains were serotype 9V; 18 (27%) were serotype 14; and 
5 (7%) were serotype 11A. Among the 43 antimicrobial 
drug–resistant strains in this cluster, 24 (56%) were sero-
type 9V, and 14 (33%) were serotype 14; others were sero-
type 11, 15C, and 19F.
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Discussion
We described the molecular and capsular types of 
pneumococci causing AOM in children tested in Rochester, 
New York, during 2004–2006. Serotype 19A, a relatively 
new molecular type, accounted for 40% of the isolates and 
has emerged as the major serotype causing ear infections 
in children. Eight different molecular STs expressed the 
19A capsule; most of the strains were multidrug resistant. 
Among the 40 strains studied, 5% were new molecular 
STs. In addition, we analyzed the genetic relatedness of 
the strains to other previously described strains of serotype 
19A. We traced the genetic origin of ST-2722 to a strain 
ﬁ  rst identiﬁ  ed in 1988 in Spain as ST-156, which expressed 
capsular serotype 9V (16). Over nearly 20 years before ST-
2722 emerged, variants of this original ST-156 strain were 
identiﬁ  ed in 18 countries, with 8 different STs and 13 dif-
ferent sequence/capsular type combinations (according to 
records in S. pneumoniae database).
ST-2722 (Legacy strain) appears to have resulted from 
a mutation identiﬁ  ed in the recP gene that coincided with 
acquisition of multidrug resistance, including a ceftriaxone 
MIC of 6.0 μg/mL, and acquisition of capsular DNA as-
sociated with the 19A serotype. Because of genetic plastic-
ity, different capsular genes of S. pneumoniae may transfer 
through DNA-mediated genetic recombination (17–19). 
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Table 1. Genotypic characteristics of Streptococcus pneumoniae serotype 19A strains with multiple antimicrobial drug resistance* 
MIC, μg/mL Allele no. of housekeeping genes†
Strain
Sequence
type Pen Cef Ery S.Tri aroE gdh gki recP spi xpt ddl
P270CR 320 2.0 1.0 >256 >32 4 16 19 15 6 20 1
060110 1451 4.0 1.0 >256 4.0 10 16 19 15 6 20 1
P270CL 320 2.0 1.0 >256 >32 4 16 19 15 6 20 1
Legacy strain 2722‡ 8.0 6.0 8.0 >32 7 11 10 15 6 8 1
P239CR 320 2.0 2.0 >256 8.0 4 16 19 5 6 20 1
0601034 320 2.0 1.0 >256 16.0 4 16 19 15 6 20 1
0601004V1NW 320 2.0 1.5 >256 6.0 4 16 19 15 6 20 1
0601004V1LMEF 320 3.0 1.5 >256 4.0 4 16 19 15 6 20 1
*Pen, benzylpenicillin; Cef, ceftriaxone; Ery, erythromycin; S.Tri, sulfamethoxazole-trimethoprim. 
†aroE (shikimate dehydrogenase), gdh (glucose-6-phosphate dehydrogenase), gki (glucose kinase), recP (transketolase), spi (signal peptidase I), xpt
(xanthine phosphoribosyltransferase), and ddl (D-alanine-D-alanine ligase). 
‡New assigned sequence type. 
10 P195CB
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0601032NWV1
0601032LMEFV1
0602017NWV1
0602017NWV2
0601003MEFV1
0601003NWV1
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P270CR (ST320)
P270CL (ST320)
0601034NS(ST320)
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P239CR(ST320)
Legacy strain (ST2722)
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P191CR
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06-02004NPV2
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strains
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Figure 1. Neighbor-joining tree of genetic relatedness among 
40  Streptococcus pneumoniae isolates from a private pediatric 
practice, Rochester, New York, USA, 2004–2006. Scale bar 
indicates genetic linkage distance.
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Figure 2. Genetic relatedness of Streptococcus pneumoniae ST-
2722 (Legacy strain) to reported types that have 5 or 6 of the same 
loci as the Legacy strain. List of types available at the multilocus 
sequence typing database (http://spneumoniae.mlst.net). Scale 
bar indicates genetic linkage distance.RESEARCH
The multidrug-resistant epidemic type 23F Spanish/USA 
clone has expressed capsular types 3, 9N, 14, and 19F. Cap-
sular transformation may equip multidrug-resistant strains 
with highly virulent blood invasive phenotypes (18).
Many studies have documented the impact of the PCV7 
on pneumococcal diseases. Introduction of PCV7 contain-
ing serotype 4, 6B, 9V, 14, 18C, 19F, and 23F has dra-
matically decreased the rate of carriage and disease caused 
by these vaccine serotypes. However, the proportion of 
invasive pneumococcal diseases caused by nonvaccine 
serotypes has increased substantially in recent years, and 
multiresistant strains have rapidly emerged (16,20–23). In 
addition, PCV7 offers moderate protection against AOM 
(24). The lowest level of protective activity provided by 
PCV7 was against serotype 19F, and 19F polysaccharide 
antigen provided less cross-protection for disease caused 
by related serotypes such as 19A (24,25). An increase in 
the rate of middle ear infections with 19A strains and other 
strains expressing capsular types not contained in PCV7 
also has been reported (11). These developments encourage 
further ongoing epidemiologic surveillance. Emergence of 
new 19A strains may represent a successful vaccine escape 
mechanism used by PCV7-targeted clones, and antimicro-
bial drug nonsusceptibility provides an additional survival 
advantage that could help these organisms spread further.
By MLST analysis and capsular typing, we found that 
multiple STs expressing capsular type 19A have emerged 
as the most important otopathogens of children. We also 
found a new strain of S. pneumoniae (ST-2722), expressing 
a 19A capsule that is resistant to all FDA-approved antimi-
crobial drugs. ST-2722 has a genetic relatedness close to 
ST-156 reported to the S. pneumoniae MLST database from 
18 countries. ST-2722 was multiresistant to antimicrobial 
drugs but had an MIC to ceftriaxone of 6.0 μg/mL. A study 
by Pelton et al. showed that multidrug-resistant 19A strains 
with ST-320 had an MIC to ceftriaxone of 8.0 μg/mL (10). 
The clinical importance of such strains is potentially high 
because empiric treatment of suspected and even proven 
pneumococcal infections typically relies on the efﬁ  cacy of 
ceftriaxone.
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Table 2. Comparison of Streptococcus pneumoniae ST-2722 (Legacy strain) with the closest types that have 6 of the same alleles as 
ST-2722*
Allele profile of housekeeping genes†
ST Serotypes aroE gdh gki recP spi xpt ddl
No. resistant/ 
total strains
Countries of 
isolation Sources
156 9V/14/11A/
15C/19F
7 11 10 1 6 8 1 38/59 BR, CA, CZ, DK, 
FR, DE, HU, IL, IT, 
LB, NL, PL, SE,
PT, QA, ES, UK, 
UY
Nasopharynx, 
cerebrospinal fluid, 
blood, pleural, 
sputum, ear
1556 14 7 11 10 12 6 8 1 1/1 DE Blood
1697 9V 7 11 10 77 6 8 1 1 UK NA
2684 11A 7 11 10 10 6 8 1 1/1 FR Nasopharynx
334 9 7 11 10 16 6 8 1 1/1 NO Blood
1893 14 7 11 10 4 6 8 1 1 NO NA
2616 14 7 11 10 2 6 8 1 1 ES Nasopharynx
1227 14 7 11 10 29 6 8 1 1/1 SE Nasopharynx
2128 9 7 11 10 5 6 8 1 1/1 UK Blood
2722 19A 7 11 10 15 6 8 1 1 US Ear
*Types reported in the multilocus sequence typing database (http://spneumoniae.mlst.net). ST, sequence type; BR, Brazil; CA, Canada; CZ, Czech 
Republic; DE, Germany; DK, Denmark; FR, France; HU, Hungary; IL, Israel; IT, Italy; LB, Lebanon; NL, Netherlands; NO, Norway; PL, Poland; SE, 
Sweden; PT, Portugal; QA, Qatar; ES, Spain; UK, United Kingdom; UY, Uruguay; US, United States; NA, not available. 
†aroE (shikimate dehydrogenase), gdh (glucose-6-phosphate dehydrogenase), gki (glucose kinase), recP (transketolase), spi (signal peptidase I), xpt
(xanthine phosphoribosyltransferase), and ddl (D-alanine-D-alanine ligase). 
Figure 3. Variable sites (colors) in recP DNA sequences (allele) of ST-
2722 (Legacy strain) and those in other Streptococcus pneumoniae 
that have the same 6 loci. List of types available at the multilocus 
sequence typing database (http://spneumoniae.mlst.net).Multidrug-Resistant S. pneumoniae and Otitis Media
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